Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask
BACKGROUND: Rates of fresh gas flow (FGF) commonly used when continuous positive airway pressure (CPAP) is delivered by face mask theoretically reduce the delivery and availability of therapeutic aerosols. As it may be hazardous for patients with acute respiratory failure to interrupt mask CPAP, the...
Gespeichert in:
Veröffentlicht in: | Thorax 1997-02, Vol.52 (2), p.171-175 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 175 |
---|---|
container_issue | 2 |
container_start_page | 171 |
container_title | Thorax |
container_volume | 52 |
creator | Parkes, S N Bersten, A D |
description | BACKGROUND: Rates of fresh gas flow (FGF) commonly used when continuous positive airway pressure (CPAP) is delivered by face mask theoretically reduce the delivery and availability of therapeutic aerosols. As it may be hazardous for patients with acute respiratory failure to interrupt mask CPAP, the effects of CPAP on aerosol kinetics and bronchodilator efficacy were investigated. METHOD: The effect of CPAP at 10 cm H2O at a FGF rate of 50 l/min on the delivery of technetium labelled aerosol generated from a readily available jet nebuliser was measured using a bench model of spontaneous respiration. In a separate clinical study the bronchodilator responses to incremental doses of nebulised salbutamol were measured in nine stable asthmatic subjects in a random sequence of conventional nebulisation (control) or nebulisation whilst receiving CPAP via a tight fitting face mask. Each patient acted as his or her own control. RESULTS: CPAP significantly reduced total aerosol delivery to the face mask from 6.85 (1.52)% to 1.3 (0.37)% of the initial nebuliser charge. In the clinical study a significant bronchodilator response to nebulised salbutamol was seen during both conventional nebulisation and nebulisation whilst receiving CPAP by face mask. The shape of the dose-response curves and the magnitude of the total increase in the forced expiratory volume in one second (FEV1) was identical for CPAP and control conditions. CONCLUSIONS: Despite a reduction in aerosol presented to the proximal airway, the bronchodilator response to inhaled beta 2 agonists in stable asthmatic subjects was not affected when CPAP was delivered by face mask. Despite a high rate of FGF, nebulised beta 2 agonists are effective when administered in conjunction with CPAP delivered by face mask. |
doi_str_mv | 10.1136/thx.52.2.171 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1758492</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3974797101</sourcerecordid><originalsourceid>FETCH-LOGICAL-b506t-e38ede8466fffc09a67ab1e25e76f43b5ae299033a28394077212558b23953a53</originalsourceid><addsrcrecordid>eNp9kUtvEzEUhUcIVEJhxxbJEgg2TPBj_JgNUhW1gBTBgoe6szye68bJxA72TGn-Pa4SRcCC1ZXu-Xx0rk9VPSd4TggT78bV3ZzTOZ0TSR5UM9IIVTPaiofVDOMG14JJ8bh6kvMaY6wIkWfVWYt52yg8q8IFpJjjgDY-wOhtRib0qEsx2FXs_WDGmBA4562xe9RPyYcbZGMYfZjilNEuZj_6W0DGp19mj3YJcp4SoB6Gsk5QzPbIGQtoa_LmafXImSHDs-M8r75fXX5bfKyXXz58Wlws645jMdbAFPSgGiGccxa3RkjTEaAcpHAN67gB2raYMUMVaxssJSWUc9VR1nJmODuv3h98d1O3hd5CGJMZ9C75rUl7HY3XfyvBr_RNvNVEctW0tBi8Phqk-HOCPOqtzxaGwQQod2upSjopZQFf_gOu45RCOa54SdIw1rD7PG8PlC2_nRO4UxSC9X2LurSoOdW0vCIFf_Fn_BN8rK3or466ydYMLplgfT5hVGCCuSpYfcB8HuHuJJu00UIyyfXnHwt9rb4ultdEalb4Nwe-267_H_A3-8vDGQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1771433435</pqid></control><display><type>article</type><title>Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Parkes, S N ; Bersten, A D</creator><creatorcontrib>Parkes, S N ; Bersten, A D</creatorcontrib><description>BACKGROUND: Rates of fresh gas flow (FGF) commonly used when continuous positive airway pressure (CPAP) is delivered by face mask theoretically reduce the delivery and availability of therapeutic aerosols. As it may be hazardous for patients with acute respiratory failure to interrupt mask CPAP, the effects of CPAP on aerosol kinetics and bronchodilator efficacy were investigated. METHOD: The effect of CPAP at 10 cm H2O at a FGF rate of 50 l/min on the delivery of technetium labelled aerosol generated from a readily available jet nebuliser was measured using a bench model of spontaneous respiration. In a separate clinical study the bronchodilator responses to incremental doses of nebulised salbutamol were measured in nine stable asthmatic subjects in a random sequence of conventional nebulisation (control) or nebulisation whilst receiving CPAP via a tight fitting face mask. Each patient acted as his or her own control. RESULTS: CPAP significantly reduced total aerosol delivery to the face mask from 6.85 (1.52)% to 1.3 (0.37)% of the initial nebuliser charge. In the clinical study a significant bronchodilator response to nebulised salbutamol was seen during both conventional nebulisation and nebulisation whilst receiving CPAP by face mask. The shape of the dose-response curves and the magnitude of the total increase in the forced expiratory volume in one second (FEV1) was identical for CPAP and control conditions. CONCLUSIONS: Despite a reduction in aerosol presented to the proximal airway, the bronchodilator response to inhaled beta 2 agonists in stable asthmatic subjects was not affected when CPAP was delivered by face mask. Despite a high rate of FGF, nebulised beta 2 agonists are effective when administered in conjunction with CPAP delivered by face mask.</description><identifier>ISSN: 0040-6376</identifier><identifier>EISSN: 1468-3296</identifier><identifier>DOI: 10.1136/thx.52.2.171</identifier><identifier>PMID: 9059480</identifier><identifier>CODEN: THORA7</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Thoracic Society</publisher><subject>Adult ; Aged ; Albuterol - administration & dosage ; Asthma - drug therapy ; Asthma - physiopathology ; Biological and medical sciences ; Bronchodilator Agents - administration & dosage ; Combined Modality Therapy ; Dose-Response Relationship, Drug ; Female ; Forced Expiratory Volume ; Humans ; Male ; Medical sciences ; Middle Aged ; Nebulizers and Vaporizers ; Pharmacology. Drug treatments ; Positive-Pressure Respiration ; Respiratory system</subject><ispartof>Thorax, 1997-02, Vol.52 (2), p.171-175</ispartof><rights>1997 INIST-CNRS</rights><rights>Copyright BMJ Publishing Group LTD Feb 1997</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b506t-e38ede8466fffc09a67ab1e25e76f43b5ae299033a28394077212558b23953a53</citedby><cites>FETCH-LOGICAL-b506t-e38ede8466fffc09a67ab1e25e76f43b5ae299033a28394077212558b23953a53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1758492/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1758492/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,725,778,782,883,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2601058$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9059480$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parkes, S N</creatorcontrib><creatorcontrib>Bersten, A D</creatorcontrib><title>Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask</title><title>Thorax</title><addtitle>Thorax</addtitle><description>BACKGROUND: Rates of fresh gas flow (FGF) commonly used when continuous positive airway pressure (CPAP) is delivered by face mask theoretically reduce the delivery and availability of therapeutic aerosols. As it may be hazardous for patients with acute respiratory failure to interrupt mask CPAP, the effects of CPAP on aerosol kinetics and bronchodilator efficacy were investigated. METHOD: The effect of CPAP at 10 cm H2O at a FGF rate of 50 l/min on the delivery of technetium labelled aerosol generated from a readily available jet nebuliser was measured using a bench model of spontaneous respiration. In a separate clinical study the bronchodilator responses to incremental doses of nebulised salbutamol were measured in nine stable asthmatic subjects in a random sequence of conventional nebulisation (control) or nebulisation whilst receiving CPAP via a tight fitting face mask. Each patient acted as his or her own control. RESULTS: CPAP significantly reduced total aerosol delivery to the face mask from 6.85 (1.52)% to 1.3 (0.37)% of the initial nebuliser charge. In the clinical study a significant bronchodilator response to nebulised salbutamol was seen during both conventional nebulisation and nebulisation whilst receiving CPAP by face mask. The shape of the dose-response curves and the magnitude of the total increase in the forced expiratory volume in one second (FEV1) was identical for CPAP and control conditions. CONCLUSIONS: Despite a reduction in aerosol presented to the proximal airway, the bronchodilator response to inhaled beta 2 agonists in stable asthmatic subjects was not affected when CPAP was delivered by face mask. Despite a high rate of FGF, nebulised beta 2 agonists are effective when administered in conjunction with CPAP delivered by face mask.</description><subject>Adult</subject><subject>Aged</subject><subject>Albuterol - administration & dosage</subject><subject>Asthma - drug therapy</subject><subject>Asthma - physiopathology</subject><subject>Biological and medical sciences</subject><subject>Bronchodilator Agents - administration & dosage</subject><subject>Combined Modality Therapy</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Forced Expiratory Volume</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nebulizers and Vaporizers</subject><subject>Pharmacology. Drug treatments</subject><subject>Positive-Pressure Respiration</subject><subject>Respiratory system</subject><issn>0040-6376</issn><issn>1468-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kUtvEzEUhUcIVEJhxxbJEgg2TPBj_JgNUhW1gBTBgoe6szye68bJxA72TGn-Pa4SRcCC1ZXu-Xx0rk9VPSd4TggT78bV3ZzTOZ0TSR5UM9IIVTPaiofVDOMG14JJ8bh6kvMaY6wIkWfVWYt52yg8q8IFpJjjgDY-wOhtRib0qEsx2FXs_WDGmBA4562xe9RPyYcbZGMYfZjilNEuZj_6W0DGp19mj3YJcp4SoB6Gsk5QzPbIGQtoa_LmafXImSHDs-M8r75fXX5bfKyXXz58Wlws645jMdbAFPSgGiGccxa3RkjTEaAcpHAN67gB2raYMUMVaxssJSWUc9VR1nJmODuv3h98d1O3hd5CGJMZ9C75rUl7HY3XfyvBr_RNvNVEctW0tBi8Phqk-HOCPOqtzxaGwQQod2upSjopZQFf_gOu45RCOa54SdIw1rD7PG8PlC2_nRO4UxSC9X2LurSoOdW0vCIFf_Fn_BN8rK3or466ydYMLplgfT5hVGCCuSpYfcB8HuHuJJu00UIyyfXnHwt9rb4ultdEalb4Nwe-267_H_A3-8vDGQ</recordid><startdate>19970201</startdate><enddate>19970201</enddate><creator>Parkes, S N</creator><creator>Bersten, A D</creator><general>BMJ Publishing Group Ltd and British Thoracic Society</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><general>BMJ Group</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19970201</creationdate><title>Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask</title><author>Parkes, S N ; Bersten, A D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b506t-e38ede8466fffc09a67ab1e25e76f43b5ae299033a28394077212558b23953a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Albuterol - administration & dosage</topic><topic>Asthma - drug therapy</topic><topic>Asthma - physiopathology</topic><topic>Biological and medical sciences</topic><topic>Bronchodilator Agents - administration & dosage</topic><topic>Combined Modality Therapy</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Forced Expiratory Volume</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nebulizers and Vaporizers</topic><topic>Pharmacology. Drug treatments</topic><topic>Positive-Pressure Respiration</topic><topic>Respiratory system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parkes, S N</creatorcontrib><creatorcontrib>Bersten, A D</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Thorax</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parkes, S N</au><au>Bersten, A D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask</atitle><jtitle>Thorax</jtitle><addtitle>Thorax</addtitle><date>1997-02-01</date><risdate>1997</risdate><volume>52</volume><issue>2</issue><spage>171</spage><epage>175</epage><pages>171-175</pages><issn>0040-6376</issn><eissn>1468-3296</eissn><coden>THORA7</coden><abstract>BACKGROUND: Rates of fresh gas flow (FGF) commonly used when continuous positive airway pressure (CPAP) is delivered by face mask theoretically reduce the delivery and availability of therapeutic aerosols. As it may be hazardous for patients with acute respiratory failure to interrupt mask CPAP, the effects of CPAP on aerosol kinetics and bronchodilator efficacy were investigated. METHOD: The effect of CPAP at 10 cm H2O at a FGF rate of 50 l/min on the delivery of technetium labelled aerosol generated from a readily available jet nebuliser was measured using a bench model of spontaneous respiration. In a separate clinical study the bronchodilator responses to incremental doses of nebulised salbutamol were measured in nine stable asthmatic subjects in a random sequence of conventional nebulisation (control) or nebulisation whilst receiving CPAP via a tight fitting face mask. Each patient acted as his or her own control. RESULTS: CPAP significantly reduced total aerosol delivery to the face mask from 6.85 (1.52)% to 1.3 (0.37)% of the initial nebuliser charge. In the clinical study a significant bronchodilator response to nebulised salbutamol was seen during both conventional nebulisation and nebulisation whilst receiving CPAP by face mask. The shape of the dose-response curves and the magnitude of the total increase in the forced expiratory volume in one second (FEV1) was identical for CPAP and control conditions. CONCLUSIONS: Despite a reduction in aerosol presented to the proximal airway, the bronchodilator response to inhaled beta 2 agonists in stable asthmatic subjects was not affected when CPAP was delivered by face mask. Despite a high rate of FGF, nebulised beta 2 agonists are effective when administered in conjunction with CPAP delivered by face mask.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Thoracic Society</pub><pmid>9059480</pmid><doi>10.1136/thx.52.2.171</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0040-6376 |
ispartof | Thorax, 1997-02, Vol.52 (2), p.171-175 |
issn | 0040-6376 1468-3296 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1758492 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
subjects | Adult Aged Albuterol - administration & dosage Asthma - drug therapy Asthma - physiopathology Biological and medical sciences Bronchodilator Agents - administration & dosage Combined Modality Therapy Dose-Response Relationship, Drug Female Forced Expiratory Volume Humans Male Medical sciences Middle Aged Nebulizers and Vaporizers Pharmacology. Drug treatments Positive-Pressure Respiration Respiratory system |
title | Aerosol kinetics and bronchodilator efficacy during continuous positive airway pressure delivered by face mask |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T11%3A52%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aerosol%20kinetics%20and%20bronchodilator%20efficacy%20during%20continuous%20positive%20airway%20pressure%20delivered%20by%20face%20mask&rft.jtitle=Thorax&rft.au=Parkes,%20S%20N&rft.date=1997-02-01&rft.volume=52&rft.issue=2&rft.spage=171&rft.epage=175&rft.pages=171-175&rft.issn=0040-6376&rft.eissn=1468-3296&rft.coden=THORA7&rft_id=info:doi/10.1136/thx.52.2.171&rft_dat=%3Cproquest_pubme%3E3974797101%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1771433435&rft_id=info:pmid/9059480&rfr_iscdi=true |